Terms: = Liver cancer AND HMGA2, HMGI-C, 8091, ENSG00000149948, LIPO, HMGIC, BABL AND Treatment
34 results:
1. Mitochondrial Dysfunction in Metabolic Dysfunction Fatty liver Disease (MAFLD).
Zhao Y; Zhou Y; Wang D; Huang Z; Xiao X; Zheng Q; Li S; Long D; Feng L
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139341
[TBL] [Abstract] [Full Text] [Related]
2. Glycyrrhizic Acid-Lipid Framework Nanovehicle Loading Triptolide for Combined Immunochemotherapy.
Xu Z; Huang Y; Wu Y; Chen J; Seto SW; Leung GP; Cai Y; Li J; Zhang J
ACS Appl Mater Interfaces; 2023 Sep; 15(35):41337-41350. PubMed ID: 37615350
[TBL] [Abstract] [Full Text] [Related]
3. Thermosensitive nanocomposite components for combined photothermal-photodynamic therapy in liver cancer treatment.
Tang W; Kang J; Yang L; Lin J; Song J; Zhou D; Ye F
Colloids Surf B Biointerfaces; 2023 Jun; 226():113317. PubMed ID: 37105064
[TBL] [Abstract] [Full Text] [Related]
4. Hepatocyte-targeted delivery using oleanolic acid-loaded liposomes for enhanced hepatocellular carcinoma therapy.
Wei X; Yang D; Xing Z; Cai J; Wang L; Zhao C; Wei X; Jiang M; Sun H; Zhou L; Fan Y; Nie H; Liu H
Biomater Sci; 2023 May; 11(11):3952-3964. PubMed ID: 37102693
[TBL] [Abstract] [Full Text] [Related]
5. Clinical implications and biological features of a novel postoperative recurrent HCC classification: A multi-centre study.
Qi LN; Ma L; Wu FX; Chen YY; Xu JX; Peng YC; Chen ZS; Gong WF; Yang CL; Wei HW; Qin SL; Shang JJ; Wang QY; Yu HP; Peng T; Huang YW; Ling YC; Tang WZ; Xiang BD; Li LQ
Liver Int; 2022 Oct; 42(10):2283-2298. PubMed ID: 35810457
[TBL] [Abstract] [Full Text] [Related]
6. The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: New insights and future directions.
Alshehade S; Alshawsh MA; Murugaiyah V; Asif M; Alshehade O; Almoustafa H; Al Zarzour RH
Life Sci; 2022 Sep; 305():120732. PubMed ID: 35760093
[TBL] [Abstract] [Full Text] [Related]
7. Multipoint Costriking Nanodevice Eliminates Primary Tumor Cells and Associated-Circulating Tumor Cells for Enhancing Metastasis Inhibition and Therapeutic Effect on HCC.
Mu W; Chu Q; Yang H; Guan L; Fu S; Gao T; Sang X; Zhang Z; Liang S; Liu Y; Zhang N
Adv Sci (Weinh); 2022 Mar; 9(9):2101472. PubMed ID: 35356152
[TBL] [Abstract] [Full Text] [Related]
8. miR-760 mediated the proliferation and metastasis of hepatocellular carcinoma cells by regulating hmga2.
Wang Q; Wang G; Xu X; Chen Z
Pathol Res Pract; 2021 Jun; 222():153420. PubMed ID: 33887625
[TBL] [Abstract] [Full Text] [Related]
9. Protein liposomes-mediated targeted acetylcholinesterase gene delivery for effective liver cancer therapy.
Wang K; Shang F; Chen D; Cao T; Wang X; Jiao J; He S; Liang X
J Nanobiotechnology; 2021 Jan; 19(1):31. PubMed ID: 33482834
[TBL] [Abstract] [Full Text] [Related]
10. Charlson comorbidity index and G8 in older old adult(≥80 years) hepatocellular carcinoma patients treated with stereotactic body radiotherapy.
Loi M; Comito T; Franzese C; Desideri I; Dominici L; Lo Faro L; Clerici E; Franceschini D; Baldaccini D; Badalamenti M; Reggiori G; Lobefalo F; Scorsetti M
J Geriatr Oncol; 2021 Sep; 12(7):1100-1103. PubMed ID: 33461945
[TBL] [Abstract] [Full Text] [Related]
11. SP94 peptide mediating highly specific and efficacious delivery of polymersomal doxorubicin hydrochloride to hepatocellular carcinoma in vivo.
Zhang J; Wang X; Cheng L; Yuan J; Zhong Z
Colloids Surf B Biointerfaces; 2021 Jan; 197():111399. PubMed ID: 33075660
[TBL] [Abstract] [Full Text] [Related]
12. A novel targeted delivery system for drug-resistant hepatocellular carcinoma therapy.
Xiao L; Hou Y; He H; Cheng S; Hou Y; Jin H; Song X; Nie G; Hou Y
Nanoscale; 2020 Aug; 12(32):17029-17044. PubMed ID: 32780053
[TBL] [Abstract] [Full Text] [Related]
13. Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response.
Ji W; Li L; Zhou S; Qiu L; Qian Z; Zhang H; Zhao P
J Drug Target; 2020 Nov; 28(9):982-990. PubMed ID: 32379004
[TBL] [Abstract] [Full Text] [Related]
14. Insulin Adverse Events.
Ludvigsson J
Pediatr Endocrinol Rev; 2020 Mar; 17(Suppl 1):183-190. PubMed ID: 32208562
[TBL] [Abstract] [Full Text] [Related]
15. SNHG16 as the miRNA let-7b-5p sponge facilitates the G2/M and epithelial-mesenchymal transition by regulating CDC25B and hmga2 expression in hepatocellular carcinoma.
Li S; Peng F; Ning Y; Jiang P; Peng J; Ding X; Zhang J; Jiang T; Xiang S
J Cell Biochem; 2020 Mar; 121(3):2543-2558. PubMed ID: 31696971
[TBL] [Abstract] [Full Text] [Related]
16. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo.
Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z
Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765
[TBL] [Abstract] [Full Text] [Related]
17. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo.
Fang Y; Yang W; Cheng L; Meng F; Zhang J; Zhong Z
Acta Biomater; 2017 Dec; 64():323-333. PubMed ID: 29030307
[TBL] [Abstract] [Full Text] [Related]
18. The let-7/Lin28 axis regulates activation of hepatic stellate cells in alcoholic liver injury.
McDaniel K; Huang L; Sato K; Wu N; Annable T; Zhou T; Ramos-Lorenzo S; Wan Y; Huang Q; Francis H; Glaser S; Tsukamoto H; Alpini G; Meng F
J Biol Chem; 2017 Jul; 292(27):11336-11347. PubMed ID: 28536261
[TBL] [Abstract] [Full Text] [Related]
19. EGF receptor targeted lipo-oligocation polyplexes for antitumoral siRNA and miRNA delivery.
Müller K; Klein PM; Heissig P; Roidl A; Wagner E
Nanotechnology; 2016 Nov; 27(46):464001. PubMed ID: 27736810
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy of trabectedin for the treatment of liposarcoma.
Zijoo R; von Mehren M
Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729
[TBL] [Abstract] [Full Text] [Related]
[Next]
